Added to YB: 2026-06-25
Pitch date: 2026-06-23
ERF.PA [neutral]
Eurofins Scientific SE
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide.
Market Cap
EUR 11.4B
Pitch Price
N/A
Price Target
N/A
Dividend
1.10%
EV/EBITDA
9.31
P/E
29.26
EV/Sales
2.07
Sector
Life Sciences Tools and Services
Category
growth
Eurofins Scientific (ERF France): Waiting for biopharma
ERF.PA (overview): Lab testing co guiding mid-single-digit organic growth for 2026, below 6.5% historical avg. Margins improving (22.5% in 2025, H2 seasonally stronger). Near-term drag from weather, TruGraf reimbursement suspension in US, Synlab/Netherlands integration. Key catalyst: Biopharma (>25% of rev) acceleration repeatedly promised but not yet delivered. Capital-intensive model limits deleveraging.
Read full article (2 min)